tradingkey.logo
tradingkey.logo
Search

MoonLake Immunotherapeutics

MLTX
Add to Watchlist
18.440USD
-0.550-2.90%
Close 07-31 16:00ETQuotes delayed by 15 min
1.52BMarket Cap
LossP/E TTM

MLTX Cash Flow Statement

You can access the annual and quarterly cash flow statements of MoonLake Immunotherapeutics to evaluate its financial soundness and stability.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Operating cash flows (indirect method)
Cash flow from continuing operating activities
-73.80%-66.29M
-21.29%-58.79M
-76.23%-44.54M
-95.52%-54.53M
-155.14%-38.14M
-292.68%-48.47M
-173.22%-25.27M
-129.38%-27.89M
-65.64%-14.95M
-6.45%-12.34M
1.08%-9.25M
41.43%-12.16M
36.38%-9.02M
-55.61%-11.60M
-363.27%-9.35M
---20.76M
---14.19M
---7.45M
---2.02M
Net income from continuing operations
-71.87%-69.71M
-35.83%-63.02M
-95.74%-70.69M
-126.39%-56.05M
-190.21%-40.56M
-488.23%-46.40M
-210.81%-36.11M
-100.42%-24.76M
-14.38%-13.98M
52.10%-7.89M
21.18%-11.62M
29.07%-12.35M
23.05%-12.22M
-15.01%-16.47M
-134.44%-14.74M
---17.42M
---15.88M
---14.32M
---6.29M
Operating gains losses
123.54%845.00K
-42.29%751.00K
2191.25%745.00K
2539.44%742.00K
1556.95%378.00K
39464.88%1.30M
888.30%32.52K
754.73%28.11K
593.40%22.81K
0.00%3.29K
-0.09%3.29K
0.03%3.29K
32.23%3.29K
32.25%3.29K
45.00%3.29K
--3.29K
--2.49K
--2.49K
--2.27K
Other non-cash items
260.83%433.00K
91.29%-123.00K
-61.13%265.00K
-502.16%-1.34M
-29.98%120.00K
-399.35%-1.41M
1060.88%681.80K
812.16%333.20K
276.36%171.38K
213.85%471.72K
-242.21%-70.96K
-151.80%-46.79K
-44.44%45.53K
276.93%150.30K
-67.94%49.89K
--90.33K
--81.96K
---84.95K
--155.63K
Change in working capital
-2938.48%-11.21M
100.15%6.00K
158.73%21.43M
77.66%-1.19M
87.03%-369.00K
40.33%-3.90M
719.43%8.28M
-322.45%-5.32M
-600.27%-2.84M
-408.10%-6.54M
-63.27%1.01M
78.73%-1.26M
249.96%568.55K
111.80%2.12M
21.99%2.75M
---5.92M
---379.14K
--1.00M
--2.26M
-Change in receivables
-512.33%-894.00K
-94.21%-847.00K
16.19%-612.00K
-132.12%-420.00K
66.74%-146.00K
-29.76%-436.14K
-623.10%-730.25K
25.02%-180.94K
-172.15%-439.01K
-187.66%-336.11K
-132.22%-100.99K
-1083.98%-241.32K
62.73%-161.32K
567.77%383.41K
22.39%-43.49K
--24.52K
---432.80K
---81.96K
---56.03K
-Change in prepaid expenses
-3799.63%-10.10M
171.83%3.86M
-81.56%274.00K
53.00%-3.84M
132.79%273.00K
25.59%-5.37M
128.53%1.49M
-824.40%-8.18M
-175.44%-832.51K
-2507.34%-7.22M
2.62%650.10K
68.59%-884.52K
230.15%1.10M
121.33%299.73K
37766.59%633.51K
---2.82M
---847.95K
---1.41M
--1.67K
-Change in other current assets
54.12%-779.00K
100.00%0.00
110999900.00%1.11M
100100.00%1.00K
-31096.03%-1.70M
100.00%-2.00
--1.00
---1.00
---5.44K
---65.51K
----
----
----
----
----
----
----
----
----
-Change in other current liabilities
----
----
----
----
83.15%3.01M
-9.64%-1.72M
682.89%5.57M
211.74%1.66M
-53.95%1.65M
-95.57%-1.57M
-460.19%-955.20K
117.60%532.52K
58.97%3.57M
-199.32%-801.28K
24.34%265.19K
---3.03M
--2.25M
--806.74K
--213.28K
Cash from non-recurring investing activities
Cash from operating activities
-73.80%-66.29M
-21.29%-58.79M
-76.23%-44.54M
-95.52%-54.53M
-155.14%-38.14M
-292.68%-48.47M
-173.22%-25.27M
-129.38%-27.89M
-65.64%-14.95M
-6.45%-12.34M
1.08%-9.25M
41.43%-12.16M
36.38%-9.02M
-55.61%-11.60M
-363.27%-9.35M
---20.76M
---14.19M
---7.45M
---2.02M
Investing cash flow
Net cash from continuing investing activities
-100.00%0.00
-100.00%0.00
-100.00%0.00
--0.00
-83.47%35.00K
-38.32%175.57K
--132.19K
--0.00
--211.76K
28463300.00%284.63K
--0.00
100.00%0.00
-100.00%0.00
-99.99%1.00
-100.00%0.00
---2.00
--16.01K
--18.38K
--11.65K
Capital expenditures
-100.00%0.00
-100.00%0.00
-100.00%0.00
--0.00
-83.47%35.00K
-38.32%175.57K
--132.19K
--0.00
--211.76K
28463300.00%284.63K
--0.00
--0.00
-100.00%0.00
-99.99%1.00
-100.00%0.00
----
--16.01K
--18.38K
--11.65K
Net cash flow from disposal of fixed assets
-100.00%0.00
-100.00%0.00
-100.00%0.00
--0.00
-83.47%35.00K
-38.32%175.57K
--132.19K
--0.00
--211.76K
28463300.00%284.63K
--0.00
100.00%0.00
-100.00%0.00
-99.99%1.00
-100.00%0.00
---2.00
--16.01K
--18.38K
--11.65K
Net cash flow from investment products
-99.83%98.00K
79.67%-29.91M
51.34%88.40M
200.58%88.25M
296.84%56.28M
-225.61%-147.16M
133.50%58.41M
-792.19%-87.74M
-245.52%-28.59M
1083.17%117.15M
-312.96%-174.38M
--12.68M
--19.65M
--9.90M
---42.23M
----
----
----
----
Net cash flow from other investing activities
--0.00
--0.00
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Cash from non-current investing activities
Net cash flow from investing activities
-99.83%98.00K
79.70%-29.91M
51.68%88.40M
200.58%88.25M
295.27%56.25M
-226.07%-147.33M
133.42%58.28M
-792.19%-87.74M
-246.60%-28.80M
1080.30%116.87M
-312.96%-174.38M
633802550.00%12.68M
122826.62%19.65M
53976.58%9.90M
-362386.24%-42.23M
--2.00
---16.01K
---18.38K
---11.65K
Financing cash flow
Cash flow from continuous financing activities
-58.09%30.64M
47937.24%72.39M
162.16%480.00K
--0.00
43.44%73.12M
-99.47%150.71K
--183.10K
-100.00%0.00
--50.98M
749475.71%28.42M
--0.00
331.09%451.29M
-100.00%0.00
-99.97%3.79K
-100.00%0.00
--104.69M
--15.00M
--15.00M
--498.33K
Net cash flow from debt Issuance/repayment
-66.49%24.47M
---627.00K
--0.00
--0.00
--73.02M
----
----
----
----
--0.00
--0.00
----
-100.00%0.00
-100.00%0.00
--0.00
----
--15.00M
--15.00M
--0.00
Net cash flow from common stock issuance/repurchase
--6.01M
--73.02M
--0.00
--0.00
-100.00%0.00
-100.00%0.00
--0.00
--0.00
--52.54M
822092.90%31.17M
--0.00
----
-100.00%0.00
162.22%3.79K
-100.00%0.00
----
--3.79K
---6.09K
--3.28K
Net cash flow from preferred stock issuance/repurchase
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--4.89K
--495.05K
Proceeds from stock option exercised by employees
70.00%170.00K
-100.00%0.00
425.75%480.00K
--0.00
200100.00%100.00K
--150.71K
--91.30K
--0.00
---50.00
----
----
----
----
----
----
----
----
----
----
Net cash flow from other financing activities
--170.00K
--0.00
-100.00%0.00
--0.00
100.00%0.00
100.00%0.00
--91.80K
--0.00
---1.56M
---2.75M
--0.00
----
----
100.00%0.00
--0.00
----
----
---1.00
--0.00
Net cash from non-recurrent financing activities
Net cash from financing activities
-58.09%30.64M
47937.24%72.39M
162.16%480.00K
--0.00
43.44%73.12M
-99.47%150.71K
--183.10K
-100.00%0.00
--50.98M
749475.71%28.42M
--0.00
331.09%451.29M
-100.00%0.00
-99.97%3.79K
-100.00%0.00
--104.69M
--15.00M
--15.00M
--498.33K
Net cash flow
Beginning cash balance
85.40%334.52M
-6.63%350.74M
-10.53%306.68M
-40.76%271.57M
-60.01%180.43M
18.07%375.66M
-31.69%342.79M
814.52%458.44M
1042.04%451.17M
672.16%318.17M
441.26%501.79M
467.45%50.13M
391.43%39.51M
8018.17%41.20M
4443.42%92.71M
--8.83M
--8.04M
--507.56K
--2.04M
Current period cash flow changes
-139.53%-36.03M
91.69%-16.22M
34.05%44.05M
130.36%35.12M
1153.35%91.14M
-246.79%-195.23M
117.90%32.87M
-125.61%-115.65M
-31.55%7.27M
7928.16%133.00M
-256.52%-183.62M
438.50%451.66M
1235.77%10.62M
-122.56%-1.70M
-3259.80%-51.50M
--83.87M
--795.31K
--7.53M
---1.53M
Effect of exchange rate changes
-448.86%-483.00K
-78.53%91.00K
12.43%-285.00K
8329.31%1.39M
-289.35%-88.00K
554.67%423.83K
-6600.94%-325.44K
88.30%-16.90K
8786.92%46.48K
881.32%64.74K
-93.26%5.01K
-183.38%-144.52K
91.77%-535.00
-387.91%-8.29K
7495.82%74.33K
---51.00K
---6.50K
--2.88K
---1.00K
Ending cash balance
9.91%298.49M
85.40%334.52M
-6.63%350.74M
-10.53%306.68M
-40.76%271.57M
-60.01%180.43M
18.07%375.66M
-31.69%342.79M
814.52%458.44M
1042.04%451.17M
672.16%318.17M
441.26%501.79M
467.45%50.13M
391.43%39.51M
8018.17%41.20M
--92.71M
--8.83M
--8.04M
--507.56K
Free cash flow
-73.64%-66.29M
-20.85%-58.79M
-75.32%-44.54M
-95.52%-54.53M
-151.81%-38.17M
-285.22%-48.65M
-174.65%-25.41M
-129.38%-27.89M
-67.99%-15.16M
-8.91%-12.63M
1.08%-9.25M
---12.16M
36.46%-9.02M
-55.23%-11.60M
-360.61%-9.35M
----
---14.20M
---7.47M
---2.03M
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

What is operating cash flow?

Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did MoonLake Immunotherapeutics Generate?

MoonLake Immunotherapeutics generated -196.01M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did MoonLake Immunotherapeutics's Operating Cash Flow Change Year Over Year?

MoonLake Immunotherapeutics's operating cash flow increased by -68.12% year over year.

What is investing cash flow?

Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does MoonLake Immunotherapeutics Spend on Capital Expenditures?

MoonLake Immunotherapeutics spent 35.00K on capital expenditures in the most recent quarter。

What is financing cash flow?

Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has MoonLake Immunotherapeutics's Financing Cash Flow Changed?

MoonLake Immunotherapeutics used 146.00M in financing activities in the latest quarter.

What is free cash flow and why does it matter for MLTX?

Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was MoonLake Immunotherapeutics’s free cash flow in the latest quarter?

Free cash flow was -196.04M reflecting a -67.40% change from the previous year.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.